Donate to Illuminate Contact TSF
Visit us on Facebook Visit us on Twitter Visit us on YouTube Visit us on Instagram Visit us on Linkedin Visit us on Tiktok

Choose Your Language:

اهلا بك د. سارة سلامة

Posted by: The Sumaira Foundation in News & Announcements

May 26, 2023 — The Sumaira Foundation is pleased to welcome Sara Salama, MD, PhD, of Alexandra University (Egypt) to join TSF’s Medical Advisory Board. Dr. Salama’s involvement makes her the Foundation’s first Arabic-speaking key opinion leader and first member to join from Africa.

Sara Salama, MD, PhD

Sara Salama, MD, PhD, is a neurologist with 9 years of clinical and research expertise in neuroimmunological disorders. In 2014, Dr. Salama became a working member of Alexandria Neuroimmunology Unit, Egypt. In 2018, she trained for one year at Johns Hopkins NMOSD clinic. She authored many publications on NMOSD and MOGAD. Her PhD research was directed towards understanding characteristics of NMOSD in Egypt. 

Prior to her career in neuroimmunology, Dr. Salama trained in general neurology as a resident at Alexandria University hospitals from 2010-2014 where she completed her master’s degree. She became a faculty member at the Department of Neurology, Alexandria University in 2014. She obtained her PhD/ MD degree and became a lecturer of neurology/ neuroimmunology in 2019. She also received her MS specialty certification exam in the same year.

Dr Salama has more than 20 peer-reviewed original research/reviews/editorials. Her work is mainly focused on neuroimmunology and particularly NMOSD.

In 2021, Dr Salama was awarded an MSIF-ARSEP McDonald Fellowship. She is currently an honorary research fellow at university college London (UCL), UK, as part of an IMS Visual multicenter project.

Clinically Dr Salama cares for more than 100 Egyptian patients of different neuroimmunological diagnoses, she continues to care for patients face to face whenever possible as well as virtually. Her hope for the future is to epidemiologically assess the burden of NMOSD in Egypt and for those patients to gain access to approved therapies.

Industry Partners

Community Partners

WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.